The US Supreme Court ruled yesterday, June 4, that pharmaceutical company Hikma’s generic cardiovascular drug does not infringe global biopharmaceutical company Amarin’s patents covering its drug ...

WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's (HIK.L), opens new tab generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular medication Vascepa did not infringe Amarin's patents, ...

Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...

Execution infrastructure converts early commercial and supply signals into owned, cross-functional workflows with decision logic and closure tracking, preventing insights from stalling in dashboards.

The Trump administration is joining forces with Mark Cuban’s Cost Plus Drugs, Amazon Pharmacy, and GoodRx to add generic medications to the direct-to-consumer drug sales website, TrumpRx, in an ...

The chief executive of generic-drug maker Sandoz SDZ0.35%increase; up pointing triangle Group expects the market for unbranded versions of popular weight-loss medicines to be big. Just how big, though ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

Java is an object-oriented programming language. To create objects and meaningfully initialize them, a developer must use a Java constructor. Constructors are a critical part of software development ...

Analysts will be watching as a generic version of semaglutide—marketed by Novo Nordisk as Wegovy for weight loss—launches in Canada as a test case for future price erosion in the U.S. A generic ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

Merck’s guidance for the year—anticipating sales between 20 billion euros and 21 billion euros, or -1% to 2% growth— “assumes no U.S. sales of Mavenclad from March 2026 amid generic competition.” ...